AOD-9604 in Sutamarchán — Fat Loss Peptide Research Guide
AOD-9604 research guide for Sutamarchán. HGH fragment studied for fat metabolism — covers mechanism, purity standards, COA verification, and how to source AOD-9604.
AOD-9604 in Sutamarchán — Research & Sourcing Guide
For anyone in Sutamarchán looking to source AOD-9604, the first thing to know is that this compound is distributed via specialist online vendors. This concentration of supply in online vendors is ultimately a quality advantage — top vendors differentiate through analytical documentation in ways local stores never could. Separating properly characterised AOD-9604 from the rest of the market depends on three things: an HPLC chromatogram documenting ≥98% purity, mass spec data verifying the correct molecular weight, and a batch-specific endotoxin panel. The sections below cover what Sutamarchán researchers need to know about sourcing, verifying, and handling AOD-9604 for research purposes.
AOD-9604: What the Research Shows
AOD-9604 belongs to the growth hormone secretagogue (GHS) class, compounds that stimulate pulsatile growth hormone release by acting on the ghrelin receptor (GHSR-1a) or growth hormone releasing hormone (GHRH) receptor. Ipamorelin, GHRP-2, GHRP-6, and Hexarelin all work primarily through GHSR-1a agonism, producing GH pulses with varying specificity profiles. CJC-1295 and Sermorelin work through the GHRH receptor, mimicking the natural hypothalamic signal for GH release. The downstream effect in both cases is increased pulsatile GH secretion and subsequent IGF-1 production in the liver. For researchers in Sutamarchán studying the GH-IGF-1 axis, this mechanistic clarity makes the GHS class a productive experimental tool.
AOD-9604 Purchasing Guide
Before evaluating any specific vendor, build a clear picture of what a proper COA looks like — so you can recognise whether a vendor meets it. The HPLC purity trace is the most important document in the COA: it should show a clear dominant peak representing AOD-9604, with small or absent impurity peaks representing impurities — purity should be stated as ≥98%. For Sutamarchán researchers evaluating new suppliers: a test quantity before committing to research volumes before placing larger orders is the accepted approach among experienced researchers. Keep lyophilised AOD-9604 at −20°C until ready to use; reconstitute only the volume needed for upcoming use and store the rest at −20°C.
Order AOD-9604 — ships to Sutamarchán
COA-verified · International tracking · Research grade
Research compound status for AOD-9604 means safety data comes from animal studies, in-vitro work, and limited human observations — rather than the controlled trials that generate pharmaceutical safety profiles. Storage requirements for AOD-9604: lyophilised powder at minus 20°C, reconstituted solution stored refrigerated at 2-8°C and consumed within 4 weeks; reconstitute only with sterile bacteriostatic water. Endotoxin testing in the AOD-9604 COA is absolutely required — gram-negative bacterial endotoxins can trigger serious inflammatory reactions at very low concentrations, and no pricing advantage justifies skipping this verification. PubMed and bioRxiv represent the most comprehensive research databases for AOD-9604 research; favour indexed journal publications over preprints over conference abstracts or single case observations.
Frequently Asked Questions
What is the clinical trial history of AOD-9604?
AOD-9604 has undergone multiple Phase II clinical trials for obesity treatment by Metabolic Pharmaceuticals in Australia. The trials showed safety and tolerability but mixed efficacy results for weight loss. It holds GRAS (Generally Recognized As Safe) status from the FDA for food use, which is unusual for research peptides.
What is AOD-9604?
AOD-9604 is a synthetic peptide analogue of the C-terminal fragment of human growth hormone (amino acids 177-191), with an additional tyrosine residue at the N-terminus. It has been studied for fat metabolism effects, specifically lipolysis stimulation and lipogenesis inhibition, without the IGF-1-stimulating effects of full-length GH. It has undergone clinical trials for obesity treatment.
How does AOD-9604 differ from growth hormone?
AOD-9604 contains only the fat-metabolism-relevant fragment of growth hormone (the C-terminal region) without the IGF-1-stimulating N-terminal domain. This means it targets fat cells' beta-adrenergic receptors for lipolytic effects without producing the anabolic IGF-1 signaling associated with full-length GH.
